Document Detail


Recent advances in the secondary prevention of coronary heart disease.
MedLine Citation:
PMID:  15500433     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Current practice guidelines provide recommendations for the secondary prevention of coronary heart disease. Following the publication of clinical trials in recent years, this review will highlight some controversial issues: the role of angiotensin and aldosterone antagonists after acute myocardial infarction; the effects of angiotensin-converting enzyme inhibitors in patients with stable coronary heart disease and preserved left ventricular ejection fraction; high-intensity lowering of low-density lipoprotein cholesterol; use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors in the elderly; and the targeting of high-density lipoprotein cholesterol with niacin.
Authors:
Angie Veverka; Jamie L Jolly
Related Documents :
8254263 - Exploratory data analysis of hyperlipidemia on the macintosh: software tools for analys...
12703893 - Effectiveness of long-term heparin-induced extracorporeal ldl precipitation (help) in i...
9223353 - New insights into the pathogenesis and prevention of acute coronary syndromes.
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  2     ISSN:  1477-9072     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-10-25     Completed Date:  2005-01-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  877-89     Citation Subset:  IM    
Affiliation:
Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0157, USA. aveverka@wingate.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anticholesteremic Agents / therapeutic use
Coronary Disease / drug therapy,  mortality*,  prevention & control*
Female
Humans
Hypercholesterolemia / drug therapy*,  prevention & control
Male
Middle Aged
Myocardial Infarction / drug therapy*,  mortality,  prevention & control*
Practice Guidelines as Topic
Primary Prevention / methods*
Prognosis
Randomized Controlled Trials as Topic
Recurrence
Renin-Angiotensin System / drug effects
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antihypertensive medications for risk reduction of first and recurrent ischemic stroke.
Next Document:  AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.